Overview

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder.
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Ironwood Pharmaceuticals, Inc.
Treatments:
Linaclotide